3-(5-methyl-1-(3-(4-methylpiperazin-1-yl)benzyl)-1H-1,2,4-triazol-3-yl)-5-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole | 1570495-56-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 3-(5-methyl-1-(3-(4-methylpiperazin-1-yl)benzyl)-1H-1,2,4-triazol-3-yl)-5-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole
• 英文别名: 3-[5-methyl-1-[[3-(4-methylpiperazin-1-yl)phenyl]methyl]-1,2,4-triazol-3-yl]-5-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazole
• CAS: 1570495-56-5
• 化学式: C₂₄H₂₄F₃N₇O₂
• 分子量: 499.495
• InChiKey: QTVFMUDVVRUQKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  36
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  85.3
• 氢给体数：
  0
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  1-(3-bromobenzyl)-5-methyl-1H-1,2,4-triazole-3-carboxamide 在 tris-(dibenzylideneacetone)dipalladium(0) 、 盐酸羟胺 、 caesium carbonate 、 三乙胺 、 N,N-二异丙基乙胺 、 N,N'-羰基二咪唑 、 三氟乙酸酐 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 乙醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 14.0h， 生成 3-(5-methyl-1-(3-(4-methylpiperazin-1-yl)benzyl)-1H-1,2,4-triazol-3-yl)-5-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole
  参考文献：
  名称：

  [EN] HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
  [FR] MODULATEURS HÉTÉROCYCLIQUES DE L'ACTIVITÉ DU FACTEUR HIF UTILISÉS POUR LE TRAITEMENT DE MALADIES

  摘要：

  公开号：

  WO2014031936A3

文献信息

• SALTS OF HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
  申请人：Board of Regents, University of Texas System

  公开号：US20150239876A1

  公开（公告）日：2015-08-27

  The present disclosure relates to salts of heterocyclic compounds and methods that inhibit HIF pathway activity. The compounds are designed to treat or prevent cancer and other hypoxia-mediated diseases.

  本公开涉及杂环化合物的盐和抑制HIF通路活性的方法。这些化合物被设计用于治疗或预防癌症和其他缺氧介导的疾病。
• HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
  申请人：Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center

  公开号：US20140066424A1

  公开（公告）日：2014-03-06

  The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.

  本发明涉及化合物和方法，可用作HIF通路活性的抑制剂，用于治疗或预防癌症和其他缺氧介导的疾病。
• Heterocyclic modulators of HIF activity for treatment of disease
  申请人：Institute for Applied Cancer Science/The University of Texas MD Anderson Cancer Center

  公开号：US09018380B2

  公开（公告）日：2015-04-28

  The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.

  本发明涉及化合物和方法，可用作HIF通路活性的抑制剂，用于治疗或预防癌症和其他缺氧介导的疾病。
• Salts of heterocyclic modulators of HIF activity for treatment of disease
  申请人：Board of Regents, The University of Texas System

  公开号：US10363248B2

  公开（公告）日：2019-07-30

  The present disclosure relates to salts of heterocyclic compounds and methods that inhibit HIF pathway activity. The compounds are designed to treat or prevent cancer and other hypoxia-mediated diseases.

  本公开涉及抑制 HIF 通路活性的杂环化合物盐和方法。这些化合物旨在治疗或预防癌症和其他缺氧介导的疾病。
• TREATING DIABETES WITH OXYTOCIN OR OXYTOCIN ANALOGS
  申请人：Cai Dongsheng

  公开号：US20140066373A1

  公开（公告）日：2014-03-06

  Methods are provided of treating or preventing diabetes in a subject comprising administering to the subject an amount of oxytocin or an oxytocin analog. Methods are also provided of increasing insulin secretion in a subject comprising administering to the subject an amount of oxytocin or an oxytocin analog.